Last week, the Samsung Biologics agreed to fill-finish manufacture Moderna’s (MRNA.O) COVID-19 vaccine, one of four such contracts announced in South Korea. The company said that its latest plan will enable it “to provide end-to-end mRNA vaccine manufacturing services from bulk drug substance to aseptic fill-finish including labelling and packaging, as well as cold chain storage.”
